Legend Capital

Legend Capital, a subsidiary of Legend Holdings Ltd., was founded in April 2001 and is based in Beijing, China. The firm manages private equity investments across four funds, totaling up to US$700 million, focusing primarily on early-stage ventures and mid-market growth companies. Its investment strategy targets sectors including information technology, telecommunications, media, healthcare, consumer goods, clean technology, and advanced manufacturing, with a strong emphasis on businesses that are either based in China or related to Chinese markets. Legend Capital is known for its active involvement with portfolio companies, providing them with essential business resources and tailored services to enhance development and optimize company performance in the Chinese market. The firm has built a diverse portfolio of over 60 companies, contributing to its reputation as a respected player in China's venture capital industry.

Hao Chen

Vice Chairman

Rui Chen

Managing Director

Maggie Fu

Managing Director

Arthur Ge

Managing Director

Frank Hong

Managing Director

Xiaohong Huang

Managing Director

Yi Kang

Director

Richard Li

President

Jiaqing Li

Managing Director

Xiangyu Ouyang

Managing Director

Joon Sung Park

Managing Director

FAN Qihui

Executive Director

Hong Shangguan

Executive Director

Jenking Shao

Managing Director and Partner

Jeff Wang

Managing Director

Junfeng Wang

Managing Director

Nengguang Wang

Managing Director and CFO

Piau-Voon Wang

Managing Director

Tony Wang

Managing Director and Vice President

Ge Xinyu

Managing Director

Joe Zhou

Managing Director

Hank Zhou

Managing Director and Co-Chief Investment Officer

Linan Zhu

Chairman

Past deals in Nanotechnology

Tianfu

Series C in 2022
Nanjing Tianfu Software Co., Ltd. is a developer of custom software solutions and intelligent industrial software based in Nanjing, China. Founded in 2011, the company serves various industries, including turbomachinery, hydraulic construction, automotive, aerospace, and shipbuilding. Its offerings encompass a range of technical services, such as CAE pre- and post-processing development, special solver development, industrial design platform construction, and artificial intelligence platform development. Tianfu focuses on meeting the specific needs of its clients by providing tailored software solutions that enhance efficiency and innovation across different sectors.

Nest

Series A in 2022
Nest is a manufacturer of laboratory equipment and consumables primarily focused on the life sciences sector. The company utilizes modern production tools in a large manufacturing facility to create various products, including cytology, microbial detection, and molecular biology consumables. In addition to these offerings, Nest also provides in vitro diagnostic and medical device-related products. By continually researching and developing new fundamental supplies, Nest aims to provide affordable solutions for its customers, ensuring that laboratories have access to essential consumables for their research needs.

Tailan New Energy

Series A in 2022
Tailan New Energy is a company dedicated to the research and development of innovative energy technologies, specifically new solid-state lithium batteries and essential lithium battery materials. Co-founded by experts in lithium battery research and a seasoned industrialization team, it aims to advance the technology and commercialization of these batteries. The company also focuses on electronic special materials and resource recycling, offering a range of services that includes battery sales, battery leasing, and the sale of graphite and carbon products. Through its efforts, Tailan New Energy seeks to contribute to the evolving landscape of energy storage solutions.

Medilink Therapeutics

Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

TuringQ

Seed Round in 2022
TuringQ, established in February 2021, specializes in the research and development of quantum information technology, particularly focusing on optical quantum chips and quantum computing. The company employs lithium niobate on insulator (LNOI) photonic chips and femtosecond laser direct writing techniques to create advanced photonic circuits. TuringQ has made significant advancements in areas such as photonic quantum chips, scientific research-grade photonic quantum computers, and photonic quantum measurement and control systems. Additionally, the company is developing photonic quantum EDA software and cloud platforms aimed at enhancing capabilities in quantum computing. TuringQ's innovations target applications in intelligent computing and power engines, positioning it as a leader in the emerging field of quantum technologies.

Singlomics

Series B in 2022
Singlomics is a biotechnology company that specializes in single-cell sequencing technology to facilitate antibody drug development aimed at treating infectious diseases and cancers. The company has made significant advancements in antibody discovery, having developed neutralizing antibodies such as DXP593 and DXP604, which offer potential solutions in the fight against COVID-19. By leveraging its innovative technology, Singlomics focuses on creating targeted therapies that address critical health challenges.

Jifan Biotechnology

Series B in 2021
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

sailner

Seed Round in 2021
Sailner 3D Technology specializes in the development and sale of industrial-grade 3D printers, focusing on color and multi-material printing capabilities. The company's innovative WJP white ink filling technology enables voxel-level precision, allowing for the creation of detailed and customizable products. Sailner's 3D printing solutions find applications in various sectors, including digital medical education, surgical planning, and industrial design, as well as in the production of high-precision jewelry models. Through its commitment to research and development, Sailner aims to enhance additive manufacturing technology and provide tailored applications to meet diverse industrial needs.

TuringQ

Seed Round in 2021
TuringQ, established in February 2021, specializes in the research and development of quantum information technology, particularly focusing on optical quantum chips and quantum computing. The company employs lithium niobate on insulator (LNOI) photonic chips and femtosecond laser direct writing techniques to create advanced photonic circuits. TuringQ has made significant advancements in areas such as photonic quantum chips, scientific research-grade photonic quantum computers, and photonic quantum measurement and control systems. Additionally, the company is developing photonic quantum EDA software and cloud platforms aimed at enhancing capabilities in quantum computing. TuringQ's innovations target applications in intelligent computing and power engines, positioning it as a leader in the emerging field of quantum technologies.

Qutronix

Seed Round in 2021
Qutronix is a company focused on the development of optical quantum chips and quantum computing technologies. It aims to advance the industrialization of quantum information and intelligent technology by utilizing photonic chips. The company offers quantum secure communication services and comprehensive solutions for remote confidential control in the Internet of Things sector. Its cutting-edge three-dimensional integrated optical quantum chip, created through femtosecond laser direct writing technology, serves as a promising resource for quantum computing and processing. Additionally, Qutronix provides a platform for research into analog quantum computers, assisting clients in exploring advanced applications such as power factor optimization and quantum search algorithms, thereby fostering connections between theoretical algorithms and practical engineering solutions.

ForQaly

Series B in 2021
Developer of minimally invasive ventricular assist devices. The company's products with advantages of small trauma, large auxiliary flow, and easy to use, providing a circulation improvement plan that doctors can use conveniently and patients can afford.

LYNK Pharmaceuticals

Series B in 2021
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

BioMap

Series A in 2021
Developer of biotechnologies designed to drive new drugs research and development. The company allows scientists to model life more accurately from proteins to a system level and extract novel insights and predictions from limited data, supported by an international, cross-functional team, enabling physicians to enhance the effectiveness rate of new drugs.

Stonewise

Series B in 2021
Beijing StoneWise Technology Co., Ltd. is a technology company founded in 2018 that specializes in artificial intelligence-driven solutions for drug discovery. The company's platform integrates advanced technologies, including artificial intelligence, microfluidics, computational chemistry, and pharmacology, to enhance the efficiency and success rates of early-stage drug development. StoneWise focuses on the research and repurposing of nucleoside-based RNA polymerase inhibitors, particularly regarding their potential applications in treating COVID-19. The platform offers a variety of tools, such as medical knowledge graphs and molecular design capabilities, aimed at pharmaceutical enterprises and research institutions. By collaborating with both domestic and international experts in various scientific fields, StoneWise is committed to transforming traditional drug research methodologies and providing comprehensive solutions to improve drug discovery outcomes.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Jifan Biotechnology

Series A in 2021
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

MicuRx Pharmaceuticals

Series E in 2020
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

LYNK Pharmaceuticals

Series A in 2020
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.
Hemu (China) Biological Engineering is a Chinese blood vessel intervention medical equipment firm.

Delova Biotech

Venture Round in 2020
Delova Biotech is focused on developing non-opioid analgesics aimed at pain treatment. The company leverages its extensive research and development experience, along with advanced preparation technology platforms, to enhance existing medications and create improved new analgesics in both China and the United States. Delova Biotech employs innovative technologies, including long-acting injection methods, transdermal formulations, nano-delivery systems, prodrug modifications, and techniques to improve the solubility of insoluble drugs. Through these efforts, the company strives to provide patients with higher quality medications that can significantly enhance their quality of life.

Novast

Venture Round in 2020
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Nanovision

Series B in 2019
Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base with an additional subsidiary in Chengdu, specializes in high-speed and high-precision radiology imaging. The company focuses on the development of static CT, X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision created China's first self-developed CMOS flat panel detector, known as the Merak series. Its products are applicable in various sectors, including medical, industrial, and security, offering advanced technological support both domestically and internationally. With a significant research and development foundation, Nanovision is positioned as a key player in the radiation imaging industry.

Suzhou Ribo Life Science

Series C in 2019
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.

Inossem

Series B in 2019
Nanjing Inossem Software Technology Co., Ltd. provides enterprise application product development and consulting services. The company offers enterprise consulting services that include IT planning, supply chain consulting, ERP consulting, etc. It also focus on material management field of enterprises, and develops intelligent storage (Instock) and intelligent master data (Indata) based on the technical foundation of AI and IoT. The company was founded in 2015 and is based in Nanjing, China. It has additional offices in Canada, the United Kingdom, China, and Hong Kong.

Hongshan Information Technology

Angel Round in 2019
Hongshan Research Institute is committed to the research, development and industrialization of cutting-edge technologies in the field of information and communication in the future, and provides technology and product solutions to promote technological progress in the field of information and communication and to build a stable and sustainable industrial ecosystem.

New Horizon Health

Series C in 2019
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Puyi Biotechnology

Series A in 2018
Puyi (Shanghai) Biotechnology Co., Ltd. is a Shanghai-based company founded in 2012 that specializes in the research and development of implantable medical devices, primarily for Ear-Nose-Throat (ENT) applications. The company focuses on high-value medical devices, emphasizing material science and drug delivery technology. Puyi has developed minimally-invasive, degradable sinus stents that release medication, significantly improving patient outcomes after surgery. In addition to ENT, the company has expanded its expertise into reproductive health and medical aesthetics, establishing a unique position in the medical device market.

New Horizon Health

Series B in 2017
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Suzhou Ribo Life Science

Series B in 2017
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.

New Horizon Health

Series A in 2016
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Bionano

Series D in 2016
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Pharmaron

Private Equity Round in 2015
Pharmaron Beijing Co., Ltd. is a leading provider of research and development services for the pharmaceutical industry, serving clients across North America, Europe, Asia, and beyond. Established in 2004 and headquartered in Beijing, the company operates through four main segments: Laboratory Services, Manufacturing and Controls Services, Clinical Development, and Others. Pharmaron offers a comprehensive range of services, including laboratory chemistry, drug metabolism and pharmacokinetics, in vitro biology, safety assessments, process development, and formulation manufacturing. Additionally, the company specializes in clinical research, regulatory bioanalysis, and contract research services. By investing in its workforce and facilities, Pharmaron has positioned itself to meet the evolving needs of the life sciences sector, thereby facilitating the development and manufacturing of pharmaceutical products globally.

Noitom

Series B in 2015
Beijing Noitom Technology Limited specializes in the development of sensor-based motion capture systems tailored for various applications, including visual effects, animation, virtual reality, gaming, sports, fitness, health, education, and simulation. Founded in 2010, the company was co-founded by experts in mechanics, software, robotics, and sensor engineering, Dr. Haoyang Liu and Dr. Tristan RuoLi Dai. Noitom's focus lies in advancing the understanding of human body movement and its interaction with the environment. The company's innovative technologies integrate MEMS sensors, pattern recognition, and wireless transmission to deliver high-fidelity motion capture solutions. By emphasizing the art of motion capture, Noitom aims to redefine industry standards and enhance the capabilities of engineers, animators, and scientists.

Liangyihui

Series A in 2015
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Bionano

Series C in 2014
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.

Noitom

Series A in 2014
Beijing Noitom Technology Limited specializes in the development of sensor-based motion capture systems tailored for various applications, including visual effects, animation, virtual reality, gaming, sports, fitness, health, education, and simulation. Founded in 2010, the company was co-founded by experts in mechanics, software, robotics, and sensor engineering, Dr. Haoyang Liu and Dr. Tristan RuoLi Dai. Noitom's focus lies in advancing the understanding of human body movement and its interaction with the environment. The company's innovative technologies integrate MEMS sensors, pattern recognition, and wireless transmission to deliver high-fidelity motion capture solutions. By emphasizing the art of motion capture, Noitom aims to redefine industry standards and enhance the capabilities of engineers, animators, and scientists.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Norel System

Series A in 2013
Norel Systems Ltd. is a fabless semiconductor company headquartered in Tianjin, China, with additional sales and support offices in Shenzhen. Founded in 2009 by experienced professionals from Silicon Valley and local marketing experts, the company specializes in the design and development of complex System-on-Chip (SOC) solutions that require high-speed mixed signal expertise. Norel Systems offers advanced mobile storage solutions, including low power USB 3.0 to SATA bridge controllers, and has developed proprietary PHY IPs for various protocols such as PCIe, HDMI, and Thunderbolt. The company also focuses on Advanced Video Transport (AVT) technology, which provides scalable, real-time, visually lossless solutions for the HD video surveillance market. With a commitment to delivering high-quality products and experiences, Norel Systems aims to lead the market in providing integrated circuit solutions for mobile devices, consumer electronics, and PCs.

Shenogen Pharma Group

Series C in 2013
Shenogen Pharma Group is a drug discovery and development company.

Norel System

Venture Round in 2011
Norel Systems Ltd. is a fabless semiconductor company headquartered in Tianjin, China, with additional sales and support offices in Shenzhen. Founded in 2009 by experienced professionals from Silicon Valley and local marketing experts, the company specializes in the design and development of complex System-on-Chip (SOC) solutions that require high-speed mixed signal expertise. Norel Systems offers advanced mobile storage solutions, including low power USB 3.0 to SATA bridge controllers, and has developed proprietary PHY IPs for various protocols such as PCIe, HDMI, and Thunderbolt. The company also focuses on Advanced Video Transport (AVT) technology, which provides scalable, real-time, visually lossless solutions for the HD video surveillance market. With a commitment to delivering high-quality products and experiences, Norel Systems aims to lead the market in providing integrated circuit solutions for mobile devices, consumer electronics, and PCs.

Pharmaron

Series C in 2011
Pharmaron Beijing Co., Ltd. is a leading provider of research and development services for the pharmaceutical industry, serving clients across North America, Europe, Asia, and beyond. Established in 2004 and headquartered in Beijing, the company operates through four main segments: Laboratory Services, Manufacturing and Controls Services, Clinical Development, and Others. Pharmaron offers a comprehensive range of services, including laboratory chemistry, drug metabolism and pharmacokinetics, in vitro biology, safety assessments, process development, and formulation manufacturing. Additionally, the company specializes in clinical research, regulatory bioanalysis, and contract research services. By investing in its workforce and facilities, Pharmaron has positioned itself to meet the evolving needs of the life sciences sector, thereby facilitating the development and manufacturing of pharmaceutical products globally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.